HeartSciences Inc Warrant
HSCSW
5 hedge funds and large institutions have $16K invested in HeartSciences Inc Warrant in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
67% more funds holding
Funds holding: 3 → 5 (+2)
2.31% less ownership
Funds ownership: 58.15% → 55.84% (-2.3%)
31% less capital invested
Capital invested by funds: $23.2K → $16K (-$7.26K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$133 |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$64 |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$56 |
| 4 |
CS
Clear Street
New York
|
+$34 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$236 |
HSCSW Hedge Fund Activity: Q4 2024 in Review
5 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in HeartSciences Inc Warrant (HSCSW) for Q4 2024, worth a combined $16K — down 31% from $23.2K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new HSCSW positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $133. The largest seller was Citadel Advisors, cutting an estimated $236.
- 5 institutional investors held HeartSciences Inc Warrant (HSCSW) as of Q4 2024, up from 3 in Q3 2024.
- Funds reported $16K of HeartSciences Inc Warrant stock for Q4 2024, down 31% quarter-over-quarter.
- 2 funds opened new HeartSciences Inc Warrant positions in Q4 2024 and 0 closed out, a net change of +2 holders.
- The largest HeartSciences Inc Warrant buyer in Q4 2024 was Armistice Capital, an estimated $133 added.
- The largest HeartSciences Inc Warrant seller in Q4 2024 was Citadel Advisors, an estimated $236 sold.
Based on aggregated 13F filings for Q4 2024.